Innovent Biologics (Suzhou) Co. Ltd.
41 active trials across 10 therapeutic areas
41
Active Trials
15
Phase 1
17
Phase 2
13
Phase 3
10
Therapeutic Areas
Portfolio Concentration: 56% of active trials in Oncology
Oncology
23 active / 77 total
Solid Tumor (Advanced)
8 active
1 Ph3
26 total since 2015
NSCLC
5 active
1 Ph3
11 total since 2015
Melanoma
3 active
5 total since 2015
Non-Hodgkin Lymphoma
2 active
8 total since 2015
SCLC
1 active
3 total since 2015
Colorectal Cancer
1 active
2 total since 2015
Pancreatic Cancer
1 active
1 Ph3
1 total since 2015
Ovarian Cancer
1 active
1 total since 2015
Multiple Myeloma
1 active
1 total since 2015
Lung Cancer (General)
0 active
4 total since 2015
Hepatocellular Carcinoma
0 active
2 total since 2015
Esophageal Cancer
0 active
2 total since 2015
Gastric Cancer
0 active
2 total since 2015
MDS
0 active
2 total since 2015
Hematologic Malignancies
0 active
1 total since 2015
Cholangiocarcinoma
0 active
1 total since 2015
Cervical Cancer
0 active
1 total since 2015
AML
0 active
1 total since 2015
Squamous Cell Carcinoma
0 active
1 total since 2015
Sarcoma
0 active
1 total since 2015
Hodgkin Lymphoma
0 active
1 total since 2015
Metabolic
9 active / 27 total
Immunology
9 active / 20 total
Cardiovascular
2 active / 2 total
Ophthalmology
1 active / 7 total
Urology
1 active / 7 total
Musculoskeletal
1 active / 3 total
Respiratory
1 active / 2 total
CNS
1 active / 1 total
Infectious Disease
0 active / 2 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)